ABBV News Alert Abbvie Inc. Common Stock (ABBV) 58.00 09/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Abbvie Inc. Common Stock (ABBV) 58.00 $ABBV

Shire Resolves Litigation Related to Vyvanse, Adderall XR - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 4:20PM CDT
Shire plc (SHPG) announced that it has reached a final agreement with the U.S. Attorney's Offices for the Eastern District of Pennsylvania and the Northern District of Illinois, all 50 states and the District of Columbia.

Pharma Stocks Review - AbbVie, Merck, Johnson and Johnson, GlaxoSmithKline, and Bristol-Myers Squibb
PR Newswire - Thu Sep 25, 8:20AM CDT
On Wednesday, September 24, 2014, the NASDAQ Composite ended at 4,555.22, up 1.03%, the Dow Jones Industrial Average advanced 0.90%, to finish the day at 17,210.06, and the S&P 500 closed at 1,998.30, up 0.78%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 755.42, up 1.68%, with the index also advancing 7.83% in the previous three months. Investor-Edge has initiated coverage on the following equities: AbbVie Inc. (NYSE: ABBV), Merck and Company Inc. (NYSE: MRK), Johnson and Johnson (NYSE: JNJ), GlaxoSmithKline PLC (NYSE: GSK), and Bristol-Myers Squibb Company (NYSE: BMY). Free research on these five companies can be accessed at:

AbbVie's HUMIRA® (adalimumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderately to Severely Active Crohn's Disease
PR Newswire - Thu Sep 25, 7:00AM CDT
AbbVie (NYSE: ABBV) announced today that the U.S. Food and Drug Administration (FDA) has approved HUMIRA® (adalimumab) for reducing signs and symptoms, and achieving and maintaining clinical remission, in pediatric Crohn's disease patients 6 years of age and older when certain other treatments have not worked well enough. This FDA approval represents the eighth indication for HUMIRA in the United States and makes it the first and only biologic treatment approved for use in this patient population that can be administered at home.

Gilead (GILD) Seeks Japanese Approval for HCV Combo Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 5:00PM CDT
Gilead (GILD) is seeking Japanese approval for the combination of Sovaldi and ledipasvir .

Celgene's Otezla Label Expanded to Include Plaque Psoriasis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 4:30PM CDT
Celgene's (CELG) Otezla gained FDA approval for plaque psoriasis.

Biotech Stock Roundup: Auxilium an Acquisition Target, Amgen Submits another BLA - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Sep 24, 10:05AM CDT
Auxilium Pharmaceuticals' (AUXL) shares soared almost 45% on a $2.2 billion acquisition proposal from Endo.

Will New Treasury Rules Contain Tax Inversions? - Analyst Blog
Swarup Gupta - Zacks Investment Research - Wed Sep 24, 9:22AM CDT
Late on Monday, the U.S. Treasury Department outlined new rules to deter domestic companies from moving abroad in an attempt to reduce tax payments.

3 Top Dividend Growth Stocks to Buy in October
Motley Fool Staff - Motley Fool - Wed Sep 24, 9:15AM CDT
Income investors have always prized dividend stocks for their steady income potential, while growth investors seek market-beating share price growth to make up for lost dividends. But what about stocks providing both dividends  and  growth? For these...

Stock Market News for September 24, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 9:10AM CDT
Markets ended in the red zone for the third consecutive day as sluggish growth data from the Eurozone and air strikes in Syria offset China’s encouraging economic data

Celgene's
at Investor's Business Daily - Tue Sep 23, 5:45PM CDT
Celgene's (CELG) Otezla received FDA approval for the oral treatment of psoriasis, which causes red, scaly patches on the skin and affects 7.5 mil Americans. It's typically treated with injections, like AbbVie's (ABBV) Humira. Celgene shares rose 1%...

Stock Market Today: U.S. Stocks in 3-Day Losing Streak as U.S. Strikes Syria
at The Street - Tue Sep 23, 3:47PM CDT
The U.S. stocks fell for a third day as U.S. fighter jets attack the Islamic State militia in Syria.

Stocks Fall To Session Lows; Vipshop Bucks The Trend
at Investor's Business Daily - Tue Sep 23, 2:00PM CDT
Selling picked up the pace in the major averages in late-afternoon trading Tuesday. The Dow Jones industrial average fell 0.6%; the S&P 500 gave up 0.4% and the Nasdaq lost 0.3%. NYSE and Nasdaq volume was tracking about 5% to 10% lower than Monday's...

U.S. Treasury Cracks Down on Tax Inversions - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Tue Sep 23, 1:15PM CDT
Tax inversions could be a thing of the past thanks to new rules from the U.S. Treasury Department.

Stocks Lower In Afternoon Trading; CarMax Plunges
at Investor's Business Daily - Tue Sep 23, 12:23PM CDT
The market was lower in afternoon trading Tuesday in what is proving to be an erratic session. The Nasdaq was down 0.1%, the S&P 500 0.3% and the Dow Jones industrial average 0.4%. Volume was tracking lower across the board. The stock market today...

Shares Feel The Squeeze Of Treasury's Inversion Rules
at Investor's Business Daily - Tue Sep 23, 11:25AM CDT
The Treasury Department's new rules cracking down on tax inversions -- U.S. companies' moving their headquarters overseas to take advantage of lower corporate tax rates -- had an immediate impact on investors as they traded down businesses so...

Why Jim Cramer Would Buy AbbVie (ABBV), St. Jude Medical (STJ) Stock on Tax Inversion News
at The Street - Tue Sep 23, 10:51AM CDT
TheStreet's Jim Cramer explains why he would buy AbbVie (ABBV) and St. Jude Medical (STJ) stock in the wake of the Treasury Department's tax inversion plan.

Why AbbVie (ABBV) Stock Is Down Today
at The Street - Tue Sep 23, 9:01AM CDT
Shares of AbbVie (ABBV) fell in morning trading Tuesday after the U.S. Treasury Department and the IRS announced a plan to decrease inversion tax benefits.

Global Tensions and Fear - Ahead of Wall Street
Sheraz Mian - Zacks Investment Research - Tue Sep 23, 8:51AM CDT
The start of an expanded air campaign in the Iraq-Syria theater and weak data out of Europe provide the unsettling backdrop for today's trading action.

Biopharmaceutical and Vaccine Production Markets to 2018
M2 - Tue Sep 23, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h2pzn6/biopharmaceutical) has announced the addition of the "Biopharmaceutical and Vaccine Production Markets" report to their offering. Though biotechnology has created many new therapies and vaccines - including products to treat cancer, diabetes, HIV/AIDS and autoimmune disorders - there are still huge challenges during the final stages of clinical drug testing for new biopharmaceuticals, as manufacturers decide when and how to risk production capital to upscale while anticipating FDA or EMA approval. During the past five years, estimates for biopharmaceuticals have varied widely as analysts and producers have juggled the promise of new drugs with the technological and financial risks of manufacturing them efficiently. Biopharmaceutical and Vaccine Production Markets examines the total biopharmaceutical manufacturing market, including in its estimates all costs related to biopharmaceutical and vaccine production. It includes the following useful information for business planning: - Market Forecasts and Estimates of Biopharmaceutical Manufacturing Costs - Vaccine Production Estimates - Trend Discussion - Production Methods - The Competitive Environment, including Contract Manufacturing and Outsourcing - Regulation of the Market - Company Profiles The report contains production segmentations for the mammalian cell, microbial cell, monoclonal antibody, other recombinant protein, vaccine, and insulin manufacturing markets, with forecasts to 2018. The current competitive environment is noted, listing selected biopharmaceutical contract manufacturers, selected top-selling biopharmaceuticals, selected Asian biomanufacturing contract manufacturing organizations (CMOs), the top 10 biopharma companies based on 2012 biopharma revenues, and the top manufacturers by global biopharmaceutical manufacturing capacity. Report profiles of major contract manufacturers: - Lonza AG - Boehringer Ingelheim GmbH - FUJIFILM Diosynth Biotechnologies - Sandoz - Royal DSM - Rentschler Biotechnologie - Celonic - BIOMEVA GmbH - ProBioGen AG - Baxter BioPharma Solutions/Baxter Bioscience Major biologics firms : - Amgen - Genentech/Roche - AbbVie Inc. (Abbott) - Biogen Idec - Regeneron Pharmaceuticals - Alexion Pharmaceuticals - Crucell /Johnson & Johnson - GlaxoSmithKline - Merck & Co. Inc - Novartis - Pfizer - Sanofi Pasteur Other contract manufacturers profiled - AAIPharma - A-Bio Pharma Pte Ltd. - ABL, Inc. - Affinity Life Sciences, Inc. - Ajinomoto Aminoscience, LLC - Alliance Medical Products, Inc. - Alpha Biologics - Biotecnol - Boston Mountain Biotech - Glycobia - Sutro Biopharma Key Topics Covered: - Executive Summary - Commercial Production - Forecasts - Regulation - Competitive Environment - Patents - Geography - Profiles For more information visit http://www.researchandmarkets.com/research/h2...maceutical




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Shanghai Import Expo Draws 4,000 Global Companies Again

Updated Category News Views 132

Shanghai spent last week making a rather pointed commercial argument: China wants to be seen buying, not merely selling. The ninth China International Import Expo, or CIIE, brought together more than 4,000 overseas companies and participants from 162 countries, regions and international organizations. That is a serious gathering by any reasonable measure, even if the...

Continue Reading
Dario's WebMD Deal Opens a Vast, Unproven Channel Path

Updated Category News Views 85

One partnership can look like a gold mine from across the valley; getting the ore out is another matter entirely. DarioHealth has struck a strategic partnership with WebMD Health Services that could put its multi-condition care platform in front of an enormous commercial ecosystem: more than 3,500 employers and 65 million covered lives. That is a meaningful distribution...

Continue Reading
Getac's Linux Certification Matters at the Rugged Edge

Updated Category News Views 73

Field computers rarely get applause, but they can decide whether a critical operation runs cleanly or turns into a very expensive mess. Getac’s November 19 announcement that its UX10, G140, and V120 rugged devices are certified for Red Hat Enterprise Linux is not the sort of headline that sends investors pounding the table. It is, however, the kind of plumbing work that...

Continue Reading
Colossal's Halloween Campaign Wins Top Communicator Honor

Updated Category News Views 28

A horror-themed fan competition putting money toward hospitalized children is not the usual awards-season material, which is precisely why Colossal's latest recognition lands with some weight. The Phoenix-based professional fundraiser received an Award of Excellence, the top honor at the 32nd annual Communicator Awards, for its Face of Halloween campaign in the Innovation...

Continue Reading
AltaPointe PATH Outreach Puts Housing Waits in Focus

Updated Category News Views 0

Two years is a brutal length of time to ask somebody without stable housing to wait for an income-based apartment. That number hangs over AltaPointe Health's PATH program in Mobile, Alabama, and it ought to. The organization helped 16 people secure permanent housing in the past fiscal year, a figure that can look small if somebody is just skimming a report. It looks very...

Continue Reading
Barcelona Housing Summit Puts Affordability on the Map

Updated Category News Views 169

A packed Barcelona hall cannot magically unjam a housing market, but it can force the grown-ups in the room to stare at the mess. Housing World Summit, known as HOWS Barcelona, closed its first edition with 1,530 attendees and a broad cast: city officials, governments, developers, investors, third-sector groups and academics. That mix matters because affordable housing is...

Continue Reading
SciBase Sets Its 2027 AGM Nominating Committee Early

Updated Category News Views 59

Four names on a committee roster rarely make anyone pound the table, and they should not. Still, SciBase Holding has put an important bit of corporate housekeeping in place for its 2027 Annual General Meeting: the nominating committee that will handle shareholder-facing governance work ahead of the May 20 meeting in Stockholm. For a small listed medical-technology...

Continue Reading
Gene Editing’s Steady Revenue Engine Is Taking Shape

Updated Category News Views 87

Gene editing is finally starting to look less like a science-fair moonshot and more like a working supply chain. That distinction matters. The latest market estimate puts the global gene editing market at $5.23 billion in 2026 and projects $8.49 billion by 2031, a 10.1% compound annual growth rate. Respectable growth, certainly, but the real investment story is not a...

Continue Reading
MSD's AI Drug Bet Has Promise, but Plenty to Prove

Updated Category News Views 66

A promising molecule remains a very expensive guess until biology agrees. That is the sober lens for MSD's newly announced research collaboration with Isomorphic Labs: potentially meaningful science, certainly interesting strategic positioning, and absolutely no reason yet to start penciling in product sales. One Oncology Target, Not a Finished Drug On November 19, 2026,...

Continue Reading
AI Search Is Squeezing Clicks, Not Killing Content Yet

Updated Category News Views 121

A search result that answers the question before earning a click is a nasty little disruption, and marketers are plainly feeling around for solid ground. Goodfirms surveyed 192 content marketing professionals for its 2026 Content Engagement Metrics report, and the headline is more resilient than the prevailing panic: 66.3% said organic website traffic grew over the prior...

Continue Reading

Top 5 Most Recently Viewed Articles

EQT AB Faces Challenges Following UBS's Rating Cut

Updated Category News Views 124

EQT AB Stock Drops After UBS Downgrade Recently, shares of EQT AB (ST:EQTAB) took a hit as UBS decided to downgrade the stock from "neutral" to "sell." This change in outlook comes amid rising worries over valuation risks and anticipated earnings in the short term. Market Response and Current Trading Situation Following the downgrade, EQT AB saw its trading price dip by...

Continue Reading
AMTD's 'The Last Dance' Sets Record in Hong Kong Film Scene

Updated Category News Views 221

AMTD's Groundbreaking Film Success AMTD Group Inc., alongside its subsidiaries AMTD IDEA Group (NYSE: AMTD; SGX: HKB) and AMTD Digital Inc. (NYSE: HKD), has achieved a remarkable milestone in the film industry with its new release, 'The Last Dance.' This film has not only shattered nine major records in Hong Kong's cinematic landscape but has also surpassed the impressive...

Continue Reading
Community Healthcare Trust Boosts Q4 Dividend Reflecting Growth

Updated Category News Views 441

Community Healthcare Trust Increases Dividend for Fourth Quarter Community Healthcare Trust Incorporated (NYSE: CHCT) has recently made an exciting announcement regarding its upcoming dividend. This decision reflects the company's ongoing commitment to delivering value to its shareholders and demonstrates its robust financial health. Many investors eagerly await the news...

Continue Reading
NielsenIQ and OpenBrand Partner to Enhance Market Insights

Updated Category News Views 1043

NielsenIQ and OpenBrand Forge a Revolutionary Alliance NielsenIQ (NIQ) stands at the forefront of consumer intelligence, and their recent partnership with OpenBrand is set to redefine the landscape of market intelligence in the consumer electronics sector. This collaboration harnesses both companies' strengths to offer advanced solutions designed for retailers,...

Continue Reading
Florida Quantum Initiative Sparks Revolutionary Tech Development

Updated Category News Views 327

Florida Quantum Initiative Launched to Boost Technology Innovation MIAMI — Just recently, leaders from Florida's technology sector proclaimed the launch of Florida Quantum, a groundbreaking initiative designed to accelerate and organize the state's quantum economy. This exciting announcement came during the eMerge Americas' Tech Basel AI Summit Miami, showcasing...

Continue Reading